[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AAVantgarde Bio Srl\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100605363",false,"NCT07161544","A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)","An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants With Stargardt Disease (STGD1) (CELESTE)","CELESTE","Inclusion Criteria:\n\n* Molecular diagnosis of Stargardt disease due to ABCA4 mutation\n* Willingness to adhere to protocol per informed consent\n\nExclusion Criteria:\n\n* Unwillingness to meet the requirements of the study\n* Participation in a clinical study with another Investigation Medicinal Product\n* Previous participation in another gene or cell therapy trial\n* Any condition that would preclude subretinal surgery\n* Complicating ocular and\u002For systemic diseases","ALL","8 Years","55 Years",{"count":20,"type":21},75,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.",[28],"Stargardt Disease",[28,30,31,32],"Biallelic Mutation","Gene Mutation","ABCA4","RECRUITING","2026-06-19",{"date":36,"type":37},"2026-06-23","ACTUAL",{"date":39,"type":37},"2025-09-29",{"date":41,"type":21},"2032-07",{"name":43,"class":44},"AAVantgarde Bio Srl","INDUSTRY",8,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100561563","NCT06591793","Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa","A Phase 1\u002F2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa","Inclusion Criteria:\n\n* Molecular diagnosis of USB1B due to MYO7A mutation\n* Willingness to adhere to protocol per informed consent\n\nExclusion Criteria:\n\n* Unwillingness to meet the requirements of the study\n* Participation in a clinical study with an Investigation Product in the past 6 months\n* Previous participation in another Gene Therapy trial\n* Any condition that would preclude subretinal surgery\n* Complicating ocular and\u002For systemic diseases","18 Years","50 Years",{"count":55,"type":21},15,[24,25],"The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.",[59],"Usher Syndrome, Type 1B",[61,62,63,64],"Usher Syndrome","MYO7A","USH1B","Retinitis Pigmentosa","2025-05-01",{"date":67,"type":37},"2025-05-02",{"date":69,"type":37},"2024-07-02",{"date":71,"type":21},"2029-07",{"name":43,"class":44},3,""]